Insulin and insulin-like growth factor 1 (IGF-1) signalling sit at the centre of how skeletal muscle controls protein turnover, glucose handling and growth. This guide is written for a laboratory and educational audience and explains what is meant by an "Insulin Grow" research compound in that context, what the published science actually shows about insulin/IGF-1 pathways in muscle, and the hazards and handling considerations relevant to in-vitro and pre-clinical work. It does not provide human dosing, medical, or therapeutic guidance. Materials discussed here are intended for research use only and are not approved medicines.

What is the "Insulin Grow" research compound?

In a research catalogue, "Insulin Grow" is a label used for materials supplied to study insulin and IGF-1 signalling in muscle and metabolic models. The scientifically meaningful entities behind such a label are the peptide hormones insulin and IGF-1, together with the receptors and intracellular cascades they activate. These are studied in cell culture and animal models to understand glucose uptake, anabolic signalling and muscle protein balance. Such research-grade materials are supplied for laboratory investigation only and have not been evaluated as treatments by the MHRA, EMA or FDA.

How does insulin and IGF-1 signalling work in muscle?

Insulin and IGF-1 bind to closely related receptor tyrosine kinases. Receptor activation phosphorylates insulin receptor substrate proteins (IRS-1/2), which recruit phosphatidylinositol-3-kinase (PI3K). PI3K generates PIP3 at the membrane, recruiting PDK1 and the kinase Akt (also called PKB). Activated Akt is a key branch point: it stimulates the mechanistic target of rapamycin complex 1 (mTORC1) to promote protein synthesis, and it phosphorylates FoxO transcription factors to suppress protein breakdown. This PI3K/Akt axis is the most studied route by which these hormones influence muscle in published models.

What does the research show about muscle growth?

Peer-reviewed work indicates that IGF-1 signalling through the Akt/mTOR pathway can drive skeletal muscle hypertrophy, while simultaneously restraining atrophy-related gene programmes controlled by FoxO and the ubiquitin-proteasome system. Genetic models reviewed by Schiaffino and Mammucari (2011) show that activating the IGF1-Akt pathway increases muscle fibre size, and that mTOR inhibition with rapamycin blunts this response. Yoshida and Delafontaine (2020) describe how the same pathway balances synthesis against degradation. These are mechanistic findings in cells and animals, not demonstrations of benefit in humans.

How is insulin/IGF-1 signalling studied in the laboratory?

Typical experimental systems include cultured myoblasts and myotubes (for example the C2C12 line), primary muscle cells, and rodent models. Common readouts include receptor and Akt phosphorylation measured by Western blot, rates of protein synthesis (such as puromycin or stable-isotope incorporation), myotube diameter, and expression of atrophy markers. Because insulin and IGF-1 are peptides, they are generally handled as reconstituted solutions added to culture media or administered parenterally in animal protocols; they are not biologically active when taken orally, which is an important reason claims of oral or capsule "dosing" do not reflect the underlying biology.

Insulin vs IGF-1: how do they compare as research targets?

Although they share much of their downstream machinery, insulin and IGF-1 are studied for different primary questions. The table below summarises commonly cited distinctions in the research literature. It is provided for educational comparison only and does not imply that either material is approved for human use.

What are the hazards and handling considerations?

Insulin and IGF-1 are biologically potent. In a laboratory they should be handled only by trained personnel under an approved risk assessment, with appropriate personal protective equipment, containment and waste disposal. The most significant hazard associated with insulin is its capacity to cause severe, potentially fatal hypoglycaemia following accidental exposure; spills, sharps and aerosols must therefore be controlled rigorously. Animal work requires ethical approval and adherence to institutional and national regulations. These materials are not for human or veterinary use and must be stored, labelled and segregated as research reagents.

Is this legal to use in the UK?

In the UK, insulin is a prescription-only medicine when used as a treatment, and supplying or administering it for human use outside regulated medical practice is unlawful. Research-grade insulin and IGF-1 materials may be obtained by bona fide laboratories for in-vitro or approved pre-clinical study, but they are not licensed medicines and must not be sold or used for human consumption. Researchers are responsible for confirming that their procurement, storage and use comply with the Human Medicines Regulations, animal-research legislation and local institutional policy. This article is not legal advice.

How should a research-grade supplier be evaluated?

For laboratory procurement, prioritise suppliers that provide a certificate of analysis, batch-level purity and identity data (for example by HPLC and mass spectrometry), clear storage and stability information, and unambiguous "research use only" labelling. Transparent documentation supports reproducibility and helps satisfy institutional record-keeping requirements. Avoid sources that make therapeutic claims or human-use suggestions, as these are inconsistent with the regulatory status of these materials.

Research references

• Yoshida T, Delafontaine P. Mechanisms of IGF-1-Mediated Regulation of Skeletal Muscle Hypertrophy and Atrophy. Cells. 2020;9(9):1970. DOI: 10.3390/cells9091970
• Schiaffino S, Mammucari C. Regulation of skeletal muscle growth by the IGF1-Akt/PKB pathway: insights from genetic models. Skeletal Muscle. 2011;1:4. DOI: 10.1186/2044-5040-1-4
• Barclay RD, Burd NA, Tyler C, Tillin NA, Mackenzie RW. The Role of the IGF-1 Signaling Cascade in Muscle Protein Synthesis and Anabolic Resistance in Aging Skeletal Muscle. Frontiers in Nutrition. 2019;6:146. DOI: 10.3389/fnut.2019.00146

Research-use disclaimer: This article is provided for laboratory and educational purposes only. The materials discussed are intended for in-vitro and approved pre-clinical research, are not approved medicines, and have not been evaluated by the MHRA, EMA or FDA. Nothing here is medical advice or an instruction for human or veterinary use.